Can conventional thyroid testing miss early autoimmune dysfunction and low T3 signaling?

Standard thyroid screenings relying solely on thyroid-stimulating hormone (TSH) and free thyroxine (FT4) to define a biochemically euthyroid state frequently fail to capture early autoimmune pathology and peripheral, tissue-level thyroid hormone signaling.

Early autoimmune detection

• Patients with early Hashimoto's or euthyroid autoimmune thyroiditis often maintain normal TSH and FT4 levels despite harboring active thyroid autoantibodies.
• Anti-thyroid peroxidase (anti-TPO) is present in up to 90% to 95% of autoimmune thyroid cases, and anti-thyroglobulin (anti-Tg) is present in 60% to 80% of cases.
• Antibody-positive euthyroid women with normal baseline TSH progress to subclinical or overt hypothyroidism at an estimated annual rate of approximately 2.1%.

Mechanistic dissociation of T3 signaling

• Roughly 80% of active, circulating triiodothyronine (T3) is generated via peripheral 5'-deiodination of T4 by D1 and D2 deiodinase enzymes.
• The pituitary gland maintains its own intracellular T3 levels and regulates TSH independently of peripheral tissues. This pituitary-systemic dissociation allows TSH to remain normal even when systemic and tissue-level T3 signaling is significantly compromised.
• Systemic stressors, inflammation, and illness down-regulate D1 and D2 and up-regulate D3, leading to reduced active T3 signaling and increased inactive reverse T3 (rT3)—a hallmark of non-thyroidal illness syndrome (NTIS) that occurs despite normal TSH and FT4 reference ranges.

Bottom line

• Conventional assessments restricted to TSH and FT4 are insufficient for detecting early autoimmune thyroiditis or peripheral tissue-specific hypothyroidism. Targeted autoantibody and peripheral T3 evaluations are necessary to identify patients with active autoimmunity or impaired T4-to-T3 conversion.